Skip to main content
. 2008 Oct 27;26(33):5352–5359. doi: 10.1200/JCO.2007.15.7461

Fig 2.

Fig 2.

(A) Distribution and frequency of unique secondary (post-imatinib) KIT mutations (per patient) in this study. One patient had different mutations in different biopsy specimens: a V654A mutation in one lesion, a D816H mutation in another (○). Impact of secondary KIT genotype on (B) progression-free survival and (C) overall survival with sunitinib.